OVERVIEW

Updates in Hepatitis B Virus: Screening, Monitoring, and Current and Emerging Therapies is organized by CME Outfitters, LLC and will be held from Jun 15, 2018 - Jun 15, 2019.

Target Audience
Primary care physicians, internists, gastroenterologists, physician assistants, nurse practitioners, nurses, and pharmacists who treat patients with HBV.

Credit Information
CME Credit (Physicians):
CME Outfitters, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Need
The Centers for Disease Control and Prevention (CDC) released the first Action Plan for the Prevention Care & Treatment of Viral Hepatitis in 2011, but despite early successes, progress in reducing the number of hepatitis B virus (HBV) infections has stalled, and HBV-related deaths have increased. The National Strategy for the Elimination of Hepatitis B and C Phase 2 Report was released in March 2017 and indicated that better attention to prevention, screening, and treatment of hepatitis B and C could eliminate the burden of these diseases and prevent nearly 90,000 deaths by 2030.

These data warranted a new action plan to address challenges and opportunities in the efforts against viral hepatitis, as there have been missed opportunities for clinicians to prevent transmission, diagnose individuals, treat HBV, and reduce the number of deaths.

The National Viral Hepatitis Action Plan 2017-2020 presents key goals and strategies for these issues, and this CME Outfitters mobile case series is designed to help primary care and internal medicine clinicians move toward achieving the Action Plan goals by testing knowledge, confidence, and performance in optimizing treatment for patients with HBV.

Learning Objectives
At the end of this CE activity, participants should be able to:
• Examine ACP and AASLD guidance updates on hepatitis B virus (HBV) screening, treatment, and monitoring.
Remain abreast of emerging treatments aimed at achieving a functional cure for HBV.

Additional details will be posted as soon as they are available.